Invivyd Seeks Emergency Use Authorization for the Pre-exposure Preventive of COVID-19

 

• EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and ongoing in vitro neutralization activity against relevant SARS-CoV-2 variants
• VYD222 demonstrates continued in vitro neutralization activity against major SARS-CoV-2 variants, including JN.1, currently the fastest growing variant in the U.S.
• Company continues preparations for potential commercial launch if EUA is granted

https://www.globenewswire.com/news-release/2024/01/03/2803175/0/en/Invivyd-Submits-Request-for-Emergency-Use-Authorization-EUA-to-U-S-FDA-for-VYD222-for-the-Pre-exposure-Prevention-of-COVID-19-in-Immunocompromised-Adults-and-Adolescents.html